Zouina SARFRAZ, Azza SARFRAZ, Muzna SARFRAZ, Hinna AFTAB, Zainab PERVAIZ

Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies

Background/aim: Since the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored. Materials and methods: A systematic search adhering to PRISMA guidelines was conducted in PubMed, Cochrane Central, medRxiv, and bioRxiv using the following keywords: “Tocilizumab,” “Actemra,” “COVID-19.” An additional subsearch was conducted on Clinicaltrials.gov to locate ongoing tocilizumab trials. Results: A total of 13 studies were included in the meta-analysis comprising 2120 patients. The treatment group had lower mortality compared to the control group (OR = 0.42, 95% CI = 0.26 to 0.69, P = 0.0005, I2 = 55%). A descriptive analysis of 50 registered trials was conducted. Conclusion: This review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality, mechanical ventilation, and the characteristics of COVID-19 registered trials.Key words: Tocilizumab, actemra, coronavirus, COVID-19, clinical trial, cytokine storm syndrome

PDF

___

1. Bryant F. COVACTA trial raises questions about tocilizumab’s benefit in COVID-19. The Lancet Rheumatology 2020; 2 (10): e592. doi: 10.1016/S2665-9913(20)30313-1
2. World Health Organisation. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019- nCoV) Infection is Suspected: Interim Guidance. WHO. 2020.
3. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y et al. Pharmaco-immunomodulatory therapy in COVID-19. Drugs 2020; 80 (13): 1267-1292. doi: 10.1007/s40265-020-01367-z
4. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology 2020; 2 (8): e474-e484. doi: 10.1016/S2665-9913(20)30173-9
5. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. European Journal of Internal Medicine 2020; 76: 31-35. doi: 10.1016/j. ejim.2020.05.009
6. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child and Adolescent Health 2020; 4 (9): 653-661. doi: 10.1016/S2352-4642(20)30177-2
7. Roumier M, Paule R, Vallée A, Rohmer J, Ballester M et al. Tocilizumab for severe worsening COVID-19 pneumonia: a propensity score analysis. Journal of Clinical Immunology 2020; 1-12. doi: 10.1007/s10875-020-00911-6
8. Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K et al. Tocilizumab for the treatment of severe coronavirus disease 2019. Journal of Medical Virology 2020; 92 (10): 2042-2049. doi: 10.1002/jmv.25964
9. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine 2020; 76: 43-49. doi: 10.1016/j. ejim.2020.05.021
10. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clinical Infectious Diseases 2020; 954. doi: 10.1093/cid/ciaa954
11. Eimer J, Vesterbacka J, Svensson AK, Stojanovic B, Wagrell C et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. Journal of Internal Medicine 2020. doi: 10.1111/joim.13162
12. Wadud N, Ahmed N, Mannu Shergil M, Khan M, Krishna MG et al. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute respiratory distress syndrome patients with tocilizumab administration. medRxiv 2020. doi: 10.1101/2020.05.13.20100081
13. Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V et al. Tocilizumab for treatment of severe covid-19 patients: preliminary results from smatteo covid19 registry (smacore). Microorganisms 2020. doi: 10.3390/microorganisms8050695
14. Ramaswamy M, Mannam P, Comer R, Sinclair E, McQuaid DB et al. Off-label real world experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community health system: a case-control study. medRxiv 2020. doi: 10.1101/2020.05.14.20099234
15. Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. Journal of Clinical Virology 2020; 129: 104444. doi: 10.1016/j.jcv.2020.104444
16. Wu R, Wang L, Kuo HCD, Shannar A, Peter R et al. An update on current therapeutic drugs treating COVID-19. Current Pharmacology Reports 2020; 1-15. doi: 10.1007/s40495-020- 00216-7
17. Rosas I, Bräu N, Waters M, Go RC, Hunter BD et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv 2020. doi: 10.1101/2020.08.27.20183442
18. Calabrese C, Rajendram P, Sacha G, Calabrese L. Practical aspects of targeting IL-6 in COVID-19 disease. Cleveland Clinic Journal of Medicine 2020. doi: 10.3949/CCJM.87A. CCC018